Daiichi Sankyo
Daiichi Sankyo Inc.
2 Hilton Court
Parsippany, NJ 07054
Phone: (973) 944-2600Website: https://dsi.com/homeCareers: careers.dsi.comPatient Assistance Program: dsi.com/patient-assistance-programs
Latest news
- FDA Approves Vanflyta (quizartinib) for Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia
20 July 2023 - Injectafer Approved in the U.S. for the Treatment of Iron Deficiency in Adult Patients with Heart Failure
5 June 2023 - Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive AML Extended by FDA
21 April 2023 - Quizartinib Granted Priority Review in the U.S. for Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia
24 October 2022 - Quizartinib Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy in Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia
11 June 2022 - Injectafer (ferric carboxymaltose injection) Receives FDA Approval for the Treatment of Pediatric Patients with Iron Deficiency Anemia
16 December 2021 - Quizartinib Added to Chemotherapy Demonstrates Superior Overall Survival Compared to Chemotherapy Alone in Adult Patients with Newly Diagnosed FLT3-ITD Positive AML
18 November 2021 - Injectafer (ferric carboxymaltose injection) Receives FDA Approval for Single Dose Option for the Treatment of Adult Patients with Iron Deficiency Anemia
6 May 2021 - FDA Approves Turalio (pexidartinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumors (TGCT) in Adults
2 August 2019 - Daiichi Sankyo Provides Update on FDA Review of Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
21 June 2019
Drugs Associated with Daiichi Sankyo Inc.
Daiichi Sankyo Inc. manufactures, markets and/or distributes more than 14 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Azor
Generic name: amlodipine/olmesartan Drug class: angiotensin II inhibitors with calcium channel blockers |
57 reviews | 8.5 / 10 |
|
Benicar
Generic name: olmesartan Drug class: angiotensin receptor blockers |
99 reviews | 7.3 / 10 |
|
Benicar HCT
Generic name: hydrochlorothiazide/olmesartan Drug class: angiotensin II inhibitors with thiazides |
26 reviews | 6.7 / 10 |
|
Effient
Generic name: prasugrel Drug class: platelet aggregation inhibitors |
20 reviews | 7.0 / 10 |
|
Enhertu
Generic name: fam-trastuzumab deruxtecan Drug class: HER2 inhibitors |
19 reviews | 7.9 / 10 |
|
Evoxac
Generic name: cevimeline Drug class: cholinergic agonists |
18 reviews | 7.2 / 10 |
|
Injectafer
Generic name: ferric carboxymaltose Drug class: iron products |
7 reviews | 7.4 / 10 |
|
Movantik
Generic name: naloxegol Drug class: peripheral opioid receptor antagonists |
238 reviews | 4.9 / 10 |
|
Savaysa
Generic name: edoxaban Drug class: factor Xa inhibitors |
2 reviews | 1.0 / 10 |
|
Tribenzor
Generic name: amlodipine/hydrochlorothiazide/olmesartan Drug class: miscellaneous antihypertensive combinations |
19 reviews | 7.5 / 10 |
|
Turalio
Generic name: pexidartinib Drug class: multikinase inhibitors |
||
|
Vanflyta
Generic name: quizartinib Drug class: multikinase inhibitors |
||
|
Welchol
Generic name: colesevelam Drug class: bile acid sequestrants |
39 reviews | 8.0 / 10 |
|
Zelboraf
Generic name: vemurafenib Drug class: multikinase inhibitors |
4 reviews | 6.2 / 10 |
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||
Discontinued Drugs
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
MorphaBond ER
Generic name: morphine Drug class: Opioids (narcotic analgesics) |
6 reviews | 2.5 / 10 |
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||
